AUTHORS
Anita Kumar, MD, Dilan Anil Patel, MD2, Christine Ryan, MD3, Yucai Wang, MD, PhD4, Philippe Armand, MD5, Nancy L. Bartlett, MD6, Alexander P. Boardman, MD7, Lauren Bumbaca, MPH8, Philip Caron, MD9, Zachary D. Crees, MD10, Lorenzo Falchi, MD11, Todd Fehniger, MD, PhD12, David C Fisher, MD13, Paul J. Hampel, MD14, Eric Jacobsen, MD15, Ashlee Joseph, BS16, Brad S. Kahl, MD17, Misty Keller18, Ann LaCasce, MD, MMSc19, Jennifer Kimberly Lue, M.D.20, Neena Mahajan21, Amira Marouf, MD, PhD22, Neha Mehta-Shah, MD, MSCI23, Hannah Mink24, Mark Murakami, MD25, Colette Owens, MD26, Corinne Parker27, Jycarra Smith28, Sarima Subzwari, MS29, Santosha Vardhana, MD, PhD30, Andrew Zelenetz, MD31, Aaron Zou32, Stephen Maxted Ansell, MD, PhD33, Gilles Salles I, MD, PhD34
AFFILIATIONS
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Washington University School of Medicine, Saint Louis, Missouri, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Mayo Clinic-Rochester, Rochester, Minnesota, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York, New York, United States
10 Washington University School of Medicine, Saint Louis, Missouri, United States
11 Memorial Sloan Kettering Cancer Center, New York, New York, United States
12 Washington University School of Medicine, Saint Louis, Missouri, United States
13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
14 Mayo Clinic-Rochester, Rochester, Minnesota, United States
15 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
16 Memorial Sloan Kettering Cancer Center, New York, New York, United States
17 Washington University School of Medicine, Saint Louis, Missouri, United States
18 Mayo Clinic-Rochester, Rochester, Minnesota, United States
19 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
20 Memorial Sloan Kettering Cancer Center, New York, New York, United States
21 Memorial Sloan Kettering Cancer Center, New York, New York, United States
22 Memorial Sloan Kettering Cancer Center, New York, New York, United States
23 Washington University School of Medicine, Saint Louis, Missouri, United States
24 Memorial Sloan Kettering Cancer Center, New York, New York, United States
25 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
26 Memorial Sloan Kettering Cancer Center, New York, New York, United States
27 Mayo Clinic-Rochester, Rochester, Minnesota, United States
28 Washington University School of Medicine, Saint Louis, Missouri, United States
29 Memorial Sloan Kettering Cancer Center, New York, New York, United States
30 Memorial Sloan Kettering Cancer Center, New York, New York, United States
31 Memorial Sloan Kettering Cancer Center, New York, New York, United States
32 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
33 Mayo Clinic-Rochester, Rochester, Minnesota, United States
34 Memorial Sloan Kettering Cancer Center, New York, New York, United States
ABSTRACT
Introduction: Effective therapies are needed for relapsed/refractory (R/R) mantle cell lymphoma (MCL), particularly after BTKi and CAR T-cell (CAR-T) failure. Pts progressing post CAR-T have dismal outcomes, with median progression-free (PFS) and overall survival (OS) of 2.5 and 5.4 months (mos), respectively (Epstein-Peterson Blood Advances 2025). The CD20xCD3 bispecific antibody glofitamab (glofit) has shown promising activity in R/R MCL (Phillips JCO 2025). Combining glofit with lenalidomide (len) may enhance T-cell and NK-cell activity, increasing antitumor cytotoxicity. In this Lymphoma Consortium (LyCon) multicenter pilot study, we report the feasibility, safety, and preliminary efficacy of glofit+len in R/R MCL.
Methods: Eligible pts had R/R MCL, ≥1 prior line of therapy, and BTKi failure. For cytokine release syndrome (CRS) mitigation, obinutuzumab (obin) 1000mg was given daily for two doses (C1D1-D2). Glofit was given IV with step-up dosing on C1D8 (2.5mg), C1D15 (10mg), then 30mg on D1 of C2-C12. Len was given orally at 10 or 20 mg based on creatinine clearance on days 1-14 of C2-C12. Up to 12 cycles were administered. Response was assessed by Lugano/LYRIC criteria; CRS and neurological adverse events (AEs) were graded per 2019 ASTCT criteria. The primary endpoint was treatment feasibility, defined as successful delivery of glofit+len during cycles 1–3 without a glofit dose delay >7 days in ≥26 of 39 pts.
Results: With data cut June 1, 2026, 39 pts were enrolled. Median age was 69 years (range, 33-84), 29 (74%) were male, 25 (64%) stage IV, 18 (46%) blastoid/pleomorphic cytology, 28 (72%) Ki67 ≥50%, 11 (28%) high-risk MIPI, 20 (51%) TP53 mutation, 21 (54%) prior CAR-T, 39 (100%) prior cBTKi, and median prior therapies 3 (range 1,8).
After obin, 2 pts had progressed rapidly and did not receive glofit. Thirty-seven pts were toxicity-evaluable. Four pts came off study before C3D1 response assessment (1 treated elsewhere; 1 died of pseudomonal sepsis; and 2 went to hospice after ICU care for grade 3 CRS/grade 4 acute kidney injury and for C. difficile colitis/hyponatremia/altered mental status, respectively), leaving 33 efficacy-evaluable pts. Of these, 17 completed 12 cycles of treatment and remain in CR, and 5 continue treatment. Of the remaining 11 pts, 6 progressed, 4 underwent allogeneic transplant, and 1 withdrew.
The primary feasibility endpoint was met (31 pts). Common treatment-related any grade (gr) AEs were neutropenia (any/gr3-4: 62%/57%), thrombocytopenia (41%/24%), and anemia (41%/8%). CRS of any gr was observed in 29/37 (78%) pts: 15 (41%) gr1, 10 (27%) gr2, and 4 (11%) gr3, all requiring ICU care. Two ICANS events (gr2, gr3) occurred and resolved ≤24 hours. Len dose reductions for AEs occurred in 6/33 pts (18%; neutropenia (n=4), non-desquamating rash (n=1), arthralgia (n=1)); 3 (9%) discontinued len for AEs (severe neutropenia (n=2) and recurrent squamous cell carcinomas (n=1)). Serious AEs occurred in 19/37 pts (51%), most commonly CRS (22%) and infection (19%).
Median follow-up was 13 mos (range 1.23-25.5). By intent-to-treat (ITT, n=39), the overall response rate (ORR) was 79% and complete response rate (CRR) was 62%. The 12-mo PFS and OS by ITT were 64% (95% CI: 48%-84%) and 67% (95% CI: 52%-86%). Among glofit-len efficacy evaluable pts (n=33), the ORR was 94% (CRR 73%). The ORR for TP53-mutated pts (n=18) was 89% (CRR 78%), and the ORR for wild-type pts (n=13) was 100% (CRR 77%). The 12-mo PFS and OS were 73% (95% CI: 57%-93%) and 77% (95% CI: 62%-97%), respectively. Median PFS and OS were not reached. Duration of CR at 12 mos was 83% (95% CI: 66%-100%). For CAR-T-naive pts (n=14), the ORR was 100% (CRR 86%); ORR for CAR-T-exposed pts (n=19) was 89% (CRR 63%). For CAR-T-naive versus –exposed pts, the 12-mo PFS estimates were 79% (95% CI: 56%-100%) vs. 68% (95% CI: 48%-97%), and the 12-mo OS estimates were 90% (95% CI: 73%-100%) vs. 67% (46%-96%), respectively.
Conclusions: The glofit and len combination was feasible to administer in R/R MCL. The safety of glofit-len was consistent with the known profiles of each agent. Early toxicity and CRS (predominantly gr1–2) were common. Glofit+len was highly active in this very high-risk patient cohort of R/R MCL, including pts who failed BTKi and CAR-T therapy. Compared to historical benchmarks, glofit+len appears to markedly improve PFS and OS for pts experiencing progression post-CAR-T therapy, warranting further investigation.
DISCLOSURES
Anita Kumar, MD: Janssen - Honoraria; AstraZeneca - Honoraria; Foresight Diagnostics - Honoraria; Lilly Pharmaceuticals - Honoraria; Genentech/Roche - Honoraria; Kite Pharmaceuticals - Honoraria; BeOne Medicines - Research Funding; Seattle Genetics - Research Funding; Lilly Pharmaceuticals - Research Funding; Adaptive Biotechnologies - Research Funding; Genentech/Roche - Research Funding; Genentech/Roche - Consultancy (Includes expert testimony)